From Boston, at a meeting of the Endocrine Society
A compound in a new class of potential anti-cholesterol drugs has passed an early test in people, researchers report.
The drug would mimic thyroid hormone, which reduces blood concentrations of low-density lipoproteins (LDL), or bad cholesterol. But the hormone also raises the risk of heart arrhythmia, osteoporosis, and muscle damage, so researchers have attempted to create a stand-in that would avoid the side effects.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.